Rapport Therapeutics, Inc.

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines for central nervous system (CNS) disorders. Its lead product candidate is RAP-219, an investigational small molecule designed to inhibit TARPy8-containing AMPARs with picomolar affinity. This candidate is being developed for focal epilepsy, peripheral neuropathic pain, and bipolar disorder. The company also has nicotinic acetylcholine receptor (nAChR) programs, including an α6 nAChR program for chronic pain and migraine, and an α9α10 nAChR program for hearing and vestibular disorders. Rapport aims to address significant unmet medical needs in CNS conditions through targeted therapies.

Rapport Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol RAPP. The trading currency is the US Dollar (USD). As a US-based company listed on a major American exchange, its shares are traded in USD, which is standard for Nasdaq-listed equities. Investors should consider currency exchange rates if they are trading from outside the United States.

Rapport Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapeutics, particularly small molecule drugs for central nervous system disorders. Biotechnology firms typically engage in high-risk, high-reward drug discovery and development, often requiring significant investment in clinical trials before potential regulatory approval. Rapport's specialization in CNS disorders places it within a niche area of biotechnology that addresses conditions like epilepsy, pain, and migraine.

Rapport Therapeutics is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2022 and was originally known as Precision Neuroscience NewCo, Inc. before rebranding to Rapport Therapeutics in October 2022. Being based in Boston places it within one of the world's leading biotech hubs, providing access to talent, research institutions, and potential partnerships. The company's recent founding reflects its status as a clinical-stage biopharmaceutical firm with a focus on CNS disorders.